In this study, we aimed to investigate the connection between peripheral blood lymphocyte subsets, phenotypes, tumor markers, and the effectiveness of combining Lenvatinib with PD-1/PD-L1 inhibitors, providing insights for personalized treatment and immunotherapy strategies. This evidence concerns the gene PDCD1 and neoplasm.